X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (39) 39
humans (38) 38
adult (28) 28
female (28) 28
aged (26) 26
male (26) 26
middle aged (25) 25
mutation (23) 23
hematology (19) 19
article (18) 18
oncology (16) 16
aged, 80 and over (15) 15
prognosis (12) 12
treatment outcome (11) 11
adolescent (10) 10
hematology, oncology and palliative medicine (10) 10
young adult (9) 9
abridged index medicus (8) 8
aml (8) 8
leukemia (8) 8
retrospective studies (8) 8
acute myeloid-leukemia (7) 7
fms-like tyrosine kinase 3 - genetics (7) 7
genetic aspects (7) 7
hemic and lymphatic diseases (7) 7
leukemia, myeloid, acute - genetics (7) 7
research (7) 7
imatinib mesylate (6) 6
therapy (6) 6
antineoplastic agents - therapeutic use (5) 5
athletes (5) 5
cancer (5) 5
care and treatment (5) 5
chronic myelogenous leukemia (5) 5
chronic myeloid leukemia (5) 5
dasatinib (5) 5
disease-free survival (5) 5
immunohistochemistry (5) 5
leukemia, myeloid, acute - drug therapy (5) 5
myelodysplastic syndromes - genetics (5) 5
protein kinase inhibitors - therapeutic use (5) 5
pyrimidines - therapeutic use (5) 5
survival rate (5) 5
tyrosine kinase inhibitors (5) 5
acute myelogenous leukemia (4) 4
analysis (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
biopsy (4) 4
dna mutational analysis (4) 4
follow-up studies (4) 4
gene (4) 4
leukemia, myeloid, acute - diagnosis (4) 4
leukemia, myeloid, acute - mortality (4) 4
minimal residual disease (4) 4
mutations (4) 4
neoplasms (4) 4
neoplasms - genetics (4) 4
pathology (4) 4
patients (4) 4
piperazines - therapeutic use (4) 4
remission induction (4) 4
stem cells (4) 4
bone marrow - pathology (3) 3
boxing (3) 3
breast-cancer (3) 3
candidates (3) 3
chronic myelomonocytic leukemia (3) 3
cytogenetics (3) 3
flt3 (3) 3
fusion proteins, bcr-abl - genetics (3) 3
gene mutations (3) 3
genomics (3) 3
imatinib (3) 3
internal tandem duplication (3) 3
medical research (3) 3
metastasis (3) 3
multidisciplinary sciences (3) 3
myelodysplastic syndromes (3) 3
myelodysplastic syndromes - diagnosis (3) 3
myelodysplastic syndromes - pathology (3) 3
myeloproliferative neoplasms (3) 3
neoplasm metastasis (3) 3
neoplasm proteins - genetics (3) 3
neoplasm staging (3) 3
olympic games (3) 3
poor-prognosis (3) 3
presidential elections (3) 3
survival analysis (3) 3
tandem repeat sequences (3) 3
thiazoles - therapeutic use (3) 3
transplantation (3) 3
tyrosine (3) 3
actionable genes (2) 2
acute myeloid leukemia (2) 2
alleles (2) 2
alpha (2) 2
antibodies, monoclonal, humanized (2) 2
bcr-abl (2) 2
benzamides (2) 2
benzamides - therapeutic use (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, pp. e0132710 - e0132710
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2018, Volume 183, Issue 5, pp. 831 - 835
Table SII. The JAK2 V617F AS-qPCR cutoff of >0.05% at day +180 following allogeneic hematopoietic stem cell transplantation reliably distinguished JAK2 V617F... 
myelofibrosis | minimal residual disease | allogeneic hematopoietic stem cell transplantation | MUTATION | MYELOPROLIFERATIVE NEOPLASMS | ASSAYS | HEMATOLOGY | Transplantation | Hematopoietic stem cells | Stem cells | Janus kinase 2 | Myelofibrosis | Index Medicus
Journal Article
American Journal of Hematology, ISSN 0361-8609, 12/2013, Volume 88, Issue 12, pp. 1024 - 1029
Most patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with tyrosine kinase inhibitors (TKI) achieve complete cytogenetic response... 
CHRONIC MYELOGENOUS LEUKEMIA | INTERFERON-ALPHA | THERAPY | CML | DASATINIB | HEMATOLOGY | ALPHA PLUS CYTARABINE | IMATINIB MESYLATE | DISCONTINUATION | NILOTINIB | REMISSION | Humans | Middle Aged | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Biomarkers, Tumor | RNA, Neoplasm - blood | Young Adult | Benzamides - therapeutic use | Fusion Proteins, bcr-abl - blood | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Neoplasm Proteins - genetics | Real-Time Polymerase Chain Reaction | Dasatinib | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Disease-Free Survival | Fusion Proteins, bcr-abl - genetics | RNA, Messenger - blood | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Survival Analysis | Neoplasm Proteins - blood | Aged | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Leukemia, Myeloid, Chronic-Phase - genetics | Tyrosine | Phenols | Care and treatment | Chronic myeloid leukemia | Analysis | Medical research | Leukemia | Index Medicus | tyrosine kinase inhibitors | chronic myeloid leukemia | molecular response | BCR-ABL
Journal Article
by Olldashi, Fatos and Muzha, Itan and Filipi, Nikolin and Lede, Roberto and Copertari, Pablo and Traverso, Carolina and Copertari, Alejandro and Vergara, Enrique Alfredo and Montenegro, Carolina and De Huidobro, Roberto Ruiz and Surt, Karina and Cialzeta, José and Lazzeri, Silvio and Piñero, Gustavo and Ciccioli, Fabiana and Videtta, Walter and Barboza, María Fernanda and Svampa, Silvana and Sciuto, Victor and Domeniconi, Gustavo and Bustamante, Marcelo and Waschbusch, Maximiliano and Gullo, María Paula and Drago, Daniel Alberto and Linares, Juan Carlos Arjona and Camputaro, Luis and Tróccoli, Gustavo and Galimberti, Hernán and Tallott, Mandy and Eybner, Christian and Buchinger, Walter and Fitzal, Sylvia and Mazairac, Guy and Oleffe, Véronique and Grollinger, Thierry and Delvaux, Philippe and Carlier, Laurent and Braet, Veronique and Jacques, Jean-Marie and De Knoop, Danielle and Nasi, Luiz and Choi, Humberto Kukhuyn and Schmitt, Mara and Gentil, André and Nacul, Flavio and Barrios, Pedro Bedoya and Xinkang, Chen and Hua, Lin Shao and Tian, Huang Han and Xiaodong, Cai and Gualteros, Wilson and Otero, Alvaro Ardila and Arango, Miguel and Ciro, Juan and Jaramillo, Hector and Garcia, Gloria and Gonzalez, Ignacio and Gomez, Carolina and Arias, Arturo and Fonseca, Marco and Mora, Carlos and Cabrera, Edgar Giovanni Luna and Betancurth, José Luis and Muñoz, Porfirio and Quiñónez, Jesus Alberto and Castillo, Maria Esther Gonzalez and Lopez, Orlando and Yepes, Rafael Perez and Cuellar, Diana Leon and Paez, Gerson and Chaves, Hernán Delgado and Ordoñez, Pablo Emilio and Plata, Ricardo and Pineda, Martha and Pulido, Libardo Enrique and Jaramillo, John Sergio Velez and Rebolledo, Carlos and Palma, Oscar and Soler, Caridad and Pastrana, Irene and Falero, Raul and Perera, Mario Domínguez and García, Agustín Arocha and Oliva, Raydel and Delgado, Hubiel López and Carnero, Aida Madrazo and López, Boris Leyva and Gallardo, Angel Lacerda and Morales, Amarilys Ortega and Lezcano, Humberto and Ferrer, Marcos Iraola and Bess, Irene Zamalea and Canino, Gladys Rivas and Ruiz, Ernesto Miguel Piferrer and Cruz, Orlando Garcia and Svoboda, Petr and Kantorová, Ilona and Ochmann, Jiří and Scheer, Peter and Kozumplík, Ladislav and ... and CRASH Trial Collaborators and CRASH trial collaborators
The Lancet, ISSN 0140-6736, 10/2004, Volume 364, Issue 9442, pp. 1321 - 1328
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2015, Volume 90, Issue 11, pp. 1065 - 1070
Journal Article